Form 4: BioAtla's Chief Medical Officer, Eric Sievers, Receives 175,000 Shares of Common Stock

Eric Sievers, Chief Medical Officer of BioAtla, Inc., acquired 175,000 shares of common stock through a restricted stock unit award.

Summary

• Eric Sievers, the Chief Medical Officer of BioAtla, Inc., filed a Form 4 to report changes in beneficial ownership.
• On March 11, 2025, Sievers acquired 175,000 shares of BioAtla common stock through a time-based restricted stock unit (RSU) award.
• The shares were acquired at a price of $0.
• The RSU will vest as to 25% of the total number of shares on March 11, 2026.
• Thereafter, 6.25% of the total number of shares subject to the RSU shall vest on the last day of each May, August, November and February, provided Sievers remains a service provider.
• Following the transaction, Sievers beneficially owns 370,032 shares of BioAtla common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The stock grant is a positive sign of alignment between management and shareholders, but it's a routine transaction.

Positives

• The grant of restricted stock units to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the Chief Medical Officer.

Future Outlook

The vesting schedule of the restricted stock units suggests an expectation of continued service from the Chief Medical Officer.

Industry Context

Stock grants and options are common forms of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include a mix of salary, bonus, and equity-based compensation.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedule of the RSU is fairly standard, with initial vesting after one year and subsequent quarterly vesting.

Stakeholder Impact

• Shareholders may view the stock grant as a positive sign of management's commitment to the company's success.
• Employees may be motivated by the fact that the Chief Medical Officer's interests are aligned with the company's performance.

Key Dates